From 01/01/2018- To 03/31/2018,
Proposal Title, ID#, Sponsor, Dates, Direct Cost, Indirect Cost, Total Cost
Burdorf, Adam F
Investigation to optimize hemodynamic management of heartmate II left ventricular assist device patients using the CardioMEMS pulmonary artery pressure sensor in advanced hart failure, 21370, St. Jude Medical Business Services, Inc., 01/18/18-01/17/20, $24,952 , $5,708 , $30,660
Desouza, Cyrus Victor
Continuation of Glycemic Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE), 15785, George Washington University, 09/06/17-07/31/18, $577,815 , $267,435 , $845,250
Midwestern Collaborative for Treating Obesity in Rural Primary Care, 18181, University of Kansas Medical Center Research Institute Inc, 01/01/18-12/31/18, $123,260 , $43,509 , $166,769
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis., 21324, Novo Nordisk Pharmaceuticals, Inc., 01/17/18-01/16/20, $0 , $16,737 , $16,737
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis., 21324, Novo Nordisk Pharmaceuticals, Inc., 01/17/18-01/16/20, $86,829 , $5,579 , $92,408
Shivaswamy, Vijay
ICA William Taylor-Prominent study at VA, 21807, Nebraska Educational Biomedical Research Association, 04/01/18-06/30/19, $20,636 , $0 , $20,636
ICA Ramesh Ramalingam-Prominent study at VA, 21806, Nebraska Educational Biomedical Research Association, 04/01/18-06/30/19, $56,247 , $0 , $56,247
Thomes, Paul G
Role of LipidDroplet Ubiquitylation in Hepatic Manifestation of Metabolic Syndrome, 21610, University of Nebraska – Lincoln, 12/08/17-05/31/18, $42,685 , $0 , $42,685
Bonasera, Stephen John
Live Well: A Mobile Intervention for Bipolar Disorder, 20614, Northwestern University-Chicago, 07/01/17-06/30/18, $1,861 , $940 , $2,801
The Care Ecosystem: Navigating Patients and Caregivers Through Stages of Dementia Care, 21403, University of California – San Francisco, 09/30/17-05/31/18, $79,112 , $40,743 , $119,855
Florescu, Diana Florentina
A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating the Safety, Pharmacokinetics and Clinical Benefit of FLU-IGIV in Hospitalized Patients with Serious Influenza A Infection, 21381, Emergent BioSolutions Canada Inc., 01/03/17-01/02/20, $0 , $7,736 , $7,736
A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating the Safety, Pharmacokinetics and Clinical Benefit of FLU-IGIV in Hospitalized Patients with Serious Influenza A Infection, 21381, Emergent BioSolutions Canada Inc., 01/03/18-01/02/20, $50,172 , $2,579 , $52,751
A Phase III, Randomized, Double-Blinde, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients, 21422, Merck Sharp & Dohme Corp., 03/23/18-03/22/20, $0 , $36,398 , $36,398
A Phase III, Randomized, Double-Blinde, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients, 21422, Merck Sharp & Dohme Corp., 03/23/18-03/22/20, $189,654 , $12,132 , $201,786
Kalil, Andre C
Rapid Assessment of Acute Illness and Injury to Enhance the U.S. Response to Public Health Emergencies, 21720, University of Southern California, 08/01/17-07/31/18, $9,435 , $4,859 , $14,294
(ARLG) Antibacterial Resistance Leadership Group: Achaogen Lung PK, 20336, Duke University, 12/01/17-11/30/18, $22,664 , $11,672 , $34,336
Rupp, Mark E
NEBRASKA ANTIMICROBIAL STEWARDSHIP ASSESSMENT AND PROMOTION (NEBRASKA ASAP) SUBAWARD, 21053, NE DHHS, 08/01/17-07/31/18, $499,589 , $14,171 , $513,760
Swindells, Susan
National AIDS Education and Training Center Grants, 530, University of Illinois – Chicago, 07/01/17-06/30/18, $48,687 , $3,895 , $52,582
AIDS Clinical Trials Group Network (ACTG), 16481, Brigham & Women's Hospital, 12/01/17-11/30/18, $16,795 , $8,489 , $25,284
AIDS Clinical Trials Group (ACTG): Protocol Chair Support, 20097, Brigham & Women's Hospital, 12/01/17-11/30/18, $3,128 , $1,575 , $4,703
Title III:Categorical Grant Program to Provide Outpatient Early Intervention Services with Respect to HIV Disease (Ryan White Part C Outpatient EIS Program), 6247, DHHS/HRSA, 01/01/18-12/31/18, $307,305 , $0 , $307,305
Vanschooneveld, Trevor Craig
Zerbaxa Medication Use Evaluation, 21321, Merck & Co, Inc., 01/30/18-01/29/20, $36,976 , $9,354 , $46,330
Baljevic, Muhamed
A Phase I/II Study of the c-Met Inhibitor Cabozantinib as a Targeted Strategy to Reverse Resistance to the Proteasome Inhibitor Carfilzomib in Refractory Multiple Myeloma, 21246, Amgen, Inc., 02/21/18-02/18/20, $0 , $26,224 , $26,224
A Phase I/II Study of the c-Met Inhibitor Cabozantinib as a Targeted Strategy to Reverse Resistance to the Proteasome Inhibitor Carfilzomib in Refractory Multiple Myeloma, 21246, Amgen, Inc., 02/21/18-02/18/20, $137,484 , $8,742 , $146,226
Bhatt, Vijaya R
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3-ITD AML, 21280, National Marrow Donor Program, 12/19/17-12/18/18, $82,729 , $20,730 , $103,459
Grem, Jean Linette
An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients with Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002, 21526, Hoosier Oncology Group, LLC, 01/26/18-01/25/19, $29,572 , $7,429 , $37,001
Gundabolu, Krishna
A Phase Ib Study of Ruxolitinib in Combination with PUH71 for the treatment of Subjects with PrimaryMyelofibrosis (PMF), Post-Polycythemia Vera MF (post- PV MF), and Post-Essential Thrombocythemia MF (post- ET MF), 21450, Samus Therapeutics, Inc., 03/12/18-03/11/20, $0 , $63,295 , $63,295
A Phase Ib Study of Ruxolitinib in Combination with PUH71 for the treatment of Subjects with PrimaryMyelofibrosis (PMF), Post-Polycythemia Vera MF (post- PV MF), and Post-Essential Thrombocythemia MF (post- ET MF), 21450, Samus Therapeutics, Inc., 03/12/18-03/11/20, $327,591 , $21,099 , $348,690
Lunning, Matthew A
An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Non Hodgkin Lymphoma, 21385, Curis, Inc., 12/19/17-12/18/19, $0 , $57,676 , $57,676
An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Non Hodgkin Lymphoma, 21385, Curis, Inc., 12/19/17-12/18/19, $298,772 , $19,225 , $317,997
Teply, Benjamin Addison
Phase II Study of Olaparib in Men with High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, with Integrated Biomarker Analysis, 21405, Johns Hopkins University, 01/16/18-01/15/20, $0 , $14,236 , $14,236
Phase II Study of Olaparib in Men with High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, with Integrated Biomarker Analysis, 21405, Johns Hopkins University, 01/16/18-01/15/20, $76,005 , $4,745 , $80,750
Murphy, P. James
A CF C3N Care Model of the Future: Proposal for Piloting a Learning Health System, 20461, Cincinnati Children's Hospital Medical Center, 01/01/18-12/31/18, $30,000 , $2,400 , $32,400
A Multi-Center, Randomized, Placebo-Controlled, Phase 1, Two-Part Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics, 21339, Proteostasis Therapeutics, Inc., 01/01/18-12/31/20, $0 , $9,746 , $9,746
A Multi-Center, Randomized, Placebo-Controlled, Phase 1, Two-Part Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics, 21339, Proteostasis Therapeutics, Inc., 01/01/18-12/31/20, $52,979 , $3,249 , $56,228
Poole, Jill Adair
Role of Pattern Recognition Receptors in Organic Dust-induced Airway Inflammation, 14123, DHHS/NIH/NIEHS, 01/01/18-12/31/18, $287,070 , $144,970 , $432,040
Rennard, Stephen Israel
Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC), 19461, University of Pittsburgh, 08/01/17-07/31/18, $6,839 , $3,454 , $10,293
RofLumilast orAzithromycin to prevent COPD Exacerbations (RELIANCE) Study, 19378, University of Illinois – Chicago, 11/29/17-12/15/18, $12,330 , $4,932 , $17,262
Thompson, Austin Bassett
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD), 20845, Boehringer Ingelheim Pharmaceuticals, Inc., 01/01/18-12/31/20, $0 , $13,181 , $13,181
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD), 20845, Boehringer Ingelheim Pharmaceuticals, Inc., 01/01/18-12/31/20, $70,596 , $4,394 , $74,990
A multi-center, double-blind, placebo-controlled, Phase 4 study in patients with pulmonary arterial hypertension to assess the effect of selexipag on daily life physical activity and patients self-reported symptoms and their impacts, 21200, Actelion Pharmaceuticals Ltd., 02/09/18-11/30/19, $0 , $13,309 , $13,309
A multi-center, double-blind, placebo-controlled, Phase 4 study in patients with pulmonary arterial hypertension to assess the effect of selexipag on daily life physical activity and patients self-reported symptoms and their impacts, 21200, Actelion Pharmaceuticals Ltd., 02/09/18-11/30/19, $71,250 , $4,436 , $75,686